New drug cocktail aims to shrink Hard-to-Treat tumors
NCT ID NCT07331155
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called LBL-024 combined with standard chemotherapy and immunotherapy for people with advanced solid tumors. About 110 adults with good overall health will receive the treatment to see if tumors shrink or stop growing. The goal is to find a safer and more effective option for those who have limited choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LBL-024 (an experimental drug) combined with chemotherapy drugs (cisplatin, paclitaxel, 5-fluorouracil, capecitabine) and tislelizumab (an immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that are hard to treat.
- What could go wrong
- This is an early Phase 2 trial with only 110 participants, so results may not apply to everyone. The combination therapy may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AnYang Tumor Hospital
NOT_YET_RECRUITINGAnyang, Henan, 455000, China
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
Suining Central Hospital
RECRUITINGSuining, Sichuan, 629099, China
-
The First Affiliated Hospital of Henan University of Science & Technology
RECRUITINGLuoyang, Henan, 471003, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 451191, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug boost the fight against esophageal cancer?
- Can a flexible dosing schedule improve esophageal cancer treatment?
- New drug cocktail targets Hard-to-Treat cancers
- New drug YL201 takes on tough esophageal cancer
- Smart MRI tailors cancer therapy for better outcomes
- New drug cocktail aims to fight tough esophageal cancer